Treatment with Vyvgart (efgartigimod alfa) may safely and effectively treat acute exacerbations and symptom worsening in people with generalized myasthenia gravis (gMG), a real-world study in China shows. The treatment demonstrated a rapid onset of action, with significant improvements seen after the first dose, as well as a…
News
Starting statins — widely prescribed medications aimed at lowering levels of the fatty molecule cholesterol — may increase the risk of developing myasthenia gravis (MG) in people across different ethnicities, a new study reported. The risk appears highest during the first six months of treatment and was more pronounced…
Ocular myasthenia gravis (OMG) patients with abnormalities in the thymus gland, antibodies against the AChR protein, or a history of smoking are at a higher risk of progression to generalized myasthenia gravis, according to a study in Thailand. Higher doses of pyridostigmine (sold as Mestinon, among others, with generics…
The immunosuppressive medications azathioprine and mycophenolate mofetil are similarly effective at controlling symptoms of generalized myasthenia gravis (gMG), but mycophenolate mofetil tends to act more quickly, according to a study in the U.S. Data also indicated that both medications were generally more effective when combined with corticosteroids, a…
Surgical removal of the thymus, or thymectomy, significantly improves nerve-muscle communication and eases symptoms and their impact on daily activities in children and adolescents with juvenile myasthenia gravis (JMG), a small U.S. study showed. After thymectomy, young patients not only showed measurable improvements in how efficiently their nerves…
In real-world practice, Vyvgart (efgartigimod alfa) is generally well tolerated and often effective for adults with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR) protein, a study showed. However, responses vary across patients and are often not durable, data showed. “These findings highlight…
Cartesian Therapeutics’ experimental cell therapy Descartes-08 outperformed a placebo at easing symptoms of generalized myasthenia gravis (gMG) in patients who test positive for self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. That’s according to a new subgroup analysis of the Phase 2b MG-001 clinical trial (NCT04146051). Previous…
Rystiggo (rozanolixizumab-noli) provides consistent symptom relief for people with generalized myasthenia gravis (gMG) across more than a dozen treatment cycles, according to a new analysis of clinical trial data. The approved UCB therapy is given as weekly subcutaneous, or under-the-skin, infusions in six-week cycles, with additional cycles…
At this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases. Bionews, the parent company of this site, sat down with John F. Crowley, president and…
Johnson & Johnson (J&J) has launched a Phase 3b clinical trial to compare the efficacy of two approved treatments for generalized myasthenia gravis (gMG). The trial, dubbed EPIC (NCT07217587), is specifically testing J&J’s Imaavy (nipocalimab) against Argenx’s Vyvgart (efgartigimod) in adults with gMG who…
Recent Posts
- I don’t want to lean on my brother too hard if he doesn’t want to lean on me
- Vyvgart shows rapid benefits for generalized myasthenia gravis: Study
- I write about living with MG because I feel too much to keep it all inside
- After my MG diagnosis, I realized the clues had been there all along
- Starting statins may increase risk of myasthenia gravis onset: Study